Rise and shine, everyone. Another brand new day is on the way and, once again, we are hustling the short people off to their various school houses. This calls, of course, for a cup of stimulation. So please join us, or grab a bottle of water if you prefer. Meanwhile, here are a few tidbits to get us all started. Have a great one and drop us a line if you hear anything interesting...
Sanofi Unwilling To Meet Genzyme Demands (Bloomberg News)
Enzon Pharma Cuts Workforce By 26 Percent (Reuters)
Johnson & Johnson Faces Thousands Of Levaquin Lawsuits (Minneapolis Star-Tribune)
Kindler Departure Sparked By Succession Issue? (Bloomberg News)
Glaxo Buys Chinese Drugmaker For $70M (Reuters)
Chris Viehbacher Is Named New PhRMA Chief (The Hill)
Medicaid Drugs Are Going To Drug Dealers (Associated Press)
Pfizer Pays NYC $25M Penalty After Transferring HQ Jobs (Bloomberg News)
Saudi Arabia Attracts Drugmakers (The Financial Times)
Sigma And API Hurt As Pfizer Goes Direct (Transport & Logistics News)
2 Comments
Busy news day.
Pfizer's loss of a tax break in NYC will be more than offset by tax incentives from other states as well as real costs savings in those states where there are lower corporate income taxes, no unions, lower pay scales and other lower cost drivers. States will welcome their business with open arms, states that don"t have a business unfriendly environment and an arrogant mayor such as in NYC.